2019
Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer.
Moss HA, Havrilesky LJ, Wang FF, Georgieva MV, Hendrix LH, Dinan MA. Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer. JCO Oncology Practice 2019, 15: e1018-e1027. PMID: 31613721, PMCID: PMC10445789, DOI: 10.1200/jop.19.00026.Peer-Reviewed Original ResearchConceptsAdvanced ovarian cancerOvarian cancerAlternative payment modelsNeoadjuvant chemotherapy patientsEmergency department visitsSEER-Medicare dataMean total costOutpatient emergency department visitsPayment modelsHealth care servicesCost-efficient careAvoidable spendingNeoadjuvant chemotherapyReal-world practiceDepartment visitsChemotherapy patientsCancer careMedicare beneficiariesHospitalizationCare servicesPatientsService MedicareChemotherapySurgeryPotential cost savings
2013
Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis. Journal Of Clinical Oncology 2013, 31: 4188-4198. PMID: 24145348, DOI: 10.1200/jco.2013.48.9021.Peer-Reviewed Original ResearchConceptsBRCA1/2 mutation carriersBRCA2 mutation carriersOvarian cancerBreast cancerMutation carriersFamily historyOC useCancer riskSystematic reviewOral contraceptive useHigh-risk womenUse of OCsBreast cancer riskOvarian cancer riskStrong family historyTiming of useOral contraceptivesCochrane DatabaseInverse associationBRCA1/2 mutationsContraceptive useElevated riskGeneral populationUnique citationsMeta-AnalysisOral Contraceptive Pills as Primary Prevention for Ovarian Cancer
Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer. Obstetrics And Gynecology 2013, 122: 139-147. PMID: 23743450, DOI: 10.1097/aog.0b013e318291c235.Peer-Reviewed Original ResearchConceptsOral contraceptive pillsUse of OCPOvarian cancer incidenceOCP useContraceptive pillsCancer incidenceOvarian cancerDuration-dependent reductionDuration-response relationshipOvarian cancer riskDuration of useCohort studyCochrane DatabasePrimary preventionSTUDY SELECTIONInclusion criteriaCancer riskDiscordant decisionsGeneral populationPrimary analysisSystematic reviewTeam reviewIncidenceSignificant reductionMore yearsOral contraceptive use for the primary prevention of ovarian cancer.
Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, Dinan M, McBroom AJ, Wing L, Musty MD, Lallinger KR, Hasselblad V, Sanders GD, Myers ER. Oral contraceptive use for the primary prevention of ovarian cancer. Evidence Report Technology Assessment 2013, 1-514. PMID: 24423062, PMCID: PMC4781074.Peer-Reviewed Original ResearchConceptsOvarian cancer preventionOral contraceptivesVascular eventsOvarian cancerOC useOC usersPrimary preventionHarm/benefit ratioCervical cancerColorectal cancerCancer incidenceCancer preventionUse of OCsPersistent human papillomavirus (HPV) infectionCurrent OC usersBenefit ratioHuman papillomavirus infectionOral contraceptive useBreast cancer incidenceOvarian cancer incidenceLife expectancyOvarian cancer outcomeRisk of breastRandom-effects modelEnglish-language studies